Sugi Predict

Sugi Predict / Compounds / SCHEMBL25753867

SCHEMBL25753867

SCHEMBL25753867

Cn1cc(Cl)c2c(c(NC(=O)OC(C)(C)C)cn2C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ BRD4 O60885 2/20 0.35
▸ BRD2 P25440 2/20 0.35
▸ BRD3 Q15059 2/20 0.35
▸ CREBBP Q92793 1/20 0.35
▸ ATR Q13535 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ ELANE P08246 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ P2RX3 P56373 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25670962 0.85 CYP17A1 (0.37) P2RX7CNR2POLBBRD4BRD2
SCHEMBL27199531 0.81 POLB (0.40) POLBGAATDP1SHMT2
SCHEMBL25754509 0.80 CNR2 (0.37) P2RX7CNR2POLBGAATDP1
SCHEMBL25756230 0.76 CNR2 (0.40) P2RX7CNR2BRD4BRD2BRD3
SCHEMBL25670291 0.75 CNR2 (0.39) P2RX7CNR2BRD4BRD2BRD3
SCHEMBL25755758 0.72 CNR2 (0.38) P2RX7CNR2BRD4BRD2BRD3
SCHEMBL20905336 0.72 P2RX7 (0.42) P2RX7CNR2POLBBRD4ATR
SCHEMBL16651233 0.70 CNR2 (0.41) P2RX7CNR2BRD4BRD2BRD3
SCHEMBL22729542 0.70 BRD4 (0.50) GAABRD4
SCHEMBL25752496 0.68 CNR2 (0.38) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 P2RX7 3505/4885CNR2 3169/4885POLB 1609/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 P2RX7 3505/4885CNR2 3169/4885POLB 1609/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 P2RX7 3505/4885CNR2 3169/4885POLB 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.